# Sermorelin vs Ipamorelin: Two Receptor Classes in the Research

> Sermorelin vs ipamorelin in the research literature: a GHRH-receptor analog versus a selective ghrelin-receptor secretagogue. The mechanism difference, the selectivity data, and how the two classes are studied together.

Two growth-hormone secretagogues, two different receptors. The verdict reads first; the GHRH-receptor-versus-ghrelin-receptor mechanism is disclosed beneath.

## The gist

**Sermorelin vs ipamorelin** comes down to which doorbell each one rings. Sermorelin is a GHRH analog — it copies the brain's natural "make growth hormone" signal and presses the GHRH receptor. Ipamorelin presses a *different* receptor (the ghrelin/GHS receptor) to get the same gland to release growth hormone by a separate route. Because the two act on different doors, research-user communities often describe pairing them. This page summarizes the mechanism difference from the published characterization studies; it is a comparison of how the molecules work, not a protocol.

## Verdict: same goal, different receptor

Sermorelin and ipamorelin both raise growth hormone, but they are not the same class of drug. Sermorelin is the GHRH(1-29) analog acting on the GHRH receptor on pituitary somatotrophs [1]. Ipamorelin was characterized as the first *selective* growth hormone secretagogue, releasing GH without significant effects on ACTH/cortisol or prolactin [9] — it acts on the ghrelin/GH-secretagogue receptor, a GHRP-class mechanism entirely distinct from GHRH signaling.

That distinction is the whole comparison. One mimics the hypothalamic GHRH signal; the other mimics ghrelin. Both converge on the same pituitary cells, but through separate receptors with separate feedback.

## The mechanism difference, disclosed

Sermorelin engages the GHRH receptor (a class B GPCR) and the Gs / cAMP / PKA cascade, preserving the body's pulsatile GH pattern and intact somatostatin/IGF-1 feedback [1]. Ipamorelin engages the ghrelin receptor, the GHRP-class pathway, and was defined by its clean selectivity profile — GH release without the cortisol or prolactin spillover seen with some earlier secretagogues [9].

The GHRP/secretagogue class also shows effects the GHRH class does not emphasize: ipamorelin and GH-releasing peptide-6 increased bone mineral content in adult female rats, an effect attributed to that secretagogue class [11]. The two classes are studied side by side precisely because they pull the same lever from different angles.

## How does sermorelin differ from direct HGH injections?

Sermorelin acts *upstream*: it tells the pituitary to release the body's own growth hormone, so the natural pulsatile rhythm and feedback through somatostatin and IGF-1 stay intact. Direct recombinant HGH supplies the hormone from outside, bypassing that regulation. An editorial argues the secretagogue route is a more physiologic approach to adult-onset GH insufficiency for exactly this reason [4].

## Sermorelin vs ipamorelin: what is the difference?

Sermorelin is a GHRH-receptor analog; ipamorelin is a selective GH secretagogue acting on the ghrelin/GHS receptor, characterized as releasing GH without significant ACTH/cortisol or prolactin effects [9]. Same destination — more growth hormone from the pituitary — reached through two different receptors and two different signaling pathways.

## What pairs well with sermorelin (e.g., ipamorelin or GHRP-2)?

Research-user communities describe pairing a GHRH analog like sermorelin with a GHRP-class secretagogue such as ipamorelin, on the rationale that the two act on different receptors [9]. This is described here as a research-context observation about mechanism, not a dosing recommendation; this site provides no protocols and no human dosing.

---

A confidence-graded intelligence brief on the GHRH(1-29) secretagogue record — each figure scored against its study, the pediatric-growth evidence held apart from the limited adult anti-aging data and the formerly-approved-now-compounded status stated plainly; no clinic behind the console and nothing here dosed, prescribed, or sold.